185 related articles for article (PubMed ID: 16330906)
1. Increased cost effectiveness with nesiritide vs. milrinone or dobutamine in the treatment of acute decompensated heart failure.
Scroggins N; Edwards M; Delgado R
Congest Heart Fail; 2005; 11(6):311-4. PubMed ID: 16330906
[TBL] [Abstract][Full Text] [Related]
2. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
[TBL] [Abstract][Full Text] [Related]
3. Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure.
Lewis DA; Gurram NR; Abraham WT; Akers WS
Am J Health Syst Pharm; 2003 Aug; 60 Suppl 4():S16-20. PubMed ID: 12966902
[TBL] [Abstract][Full Text] [Related]
4. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact.
Yamani MH; Haji SA; Starling RC; Kelly L; Albert N; Knack DL; Young JB
Am Heart J; 2001 Dec; 142(6):998-1002. PubMed ID: 11717603
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure.
Gerhard T; Zineh I; Winterstein AG; Hartzema AG
Pharmacotherapy; 2006 Jan; 26(1):34-43. PubMed ID: 16509026
[TBL] [Abstract][Full Text] [Related]
6. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure.
Silver MA; Horton DP; Ghali JK; Elkayam U
J Am Coll Cardiol; 2002 Mar; 39(5):798-803. PubMed ID: 11869844
[TBL] [Abstract][Full Text] [Related]
7. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Abraham WT; Adams KF; Fonarow GC; Costanzo MR; Berkowitz RL; LeJemtel TH; Cheng ML; Wynne J; ;
J Am Coll Cardiol; 2005 Jul; 46(1):57-64. PubMed ID: 15992636
[TBL] [Abstract][Full Text] [Related]
8. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure.
de Lissovoy G; Stier DM; Ciesla G; Munger M; Burger AJ
Am J Cardiol; 2003 Sep; 92(5):631-3. PubMed ID: 12943895
[TBL] [Abstract][Full Text] [Related]
9. The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure.
Strain WD
Int J Clin Pract; 2004 Nov; 58(11):1081-7. PubMed ID: 15605677
[TBL] [Abstract][Full Text] [Related]
10. Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure.
King JB; Shah RU; Sainski-Nguyen A; Biskupiak J; Munger MA; Bress AP
Pharmacotherapy; 2017 Jun; 37(6):662-672. PubMed ID: 28475215
[TBL] [Abstract][Full Text] [Related]
11. Dobutamine Therapy is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.
Wang XC; Zhu DM; Shan YX
Am J Cardiovasc Drugs; 2015 Dec; 15(6):429-37. PubMed ID: 26123415
[TBL] [Abstract][Full Text] [Related]
12. Acute decompensated heart failure: the shrinking role of inotropic therapy.
Dec GW
J Am Coll Cardiol; 2005 Jul; 46(1):65-7. PubMed ID: 15992637
[No Abstract] [Full Text] [Related]
13. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial.
Aranda JM; Schofield RS; Pauly DF; Cleeton TS; Walker TC; Monroe VS; Leach D; Lopez LM; Hill JA
Am Heart J; 2003 Feb; 145(2):324-9. PubMed ID: 12595851
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Positive Inotropic Agents in the Management of Acute Decompensated Heart Failure.
Kelly J; Cheng J; Malloy R; Lupi K
J Cardiovasc Pharmacol; 2020 May; 75(5):455-459. PubMed ID: 32091426
[TBL] [Abstract][Full Text] [Related]
15. Medical resource use, costs, and quality of life in patients with acute decompensated heart failure: findings from ASCEND-HF.
Reed SD; Kaul P; Li Y; Eapen ZJ; Davidson-Ray L; Schulman KA; Massie BM; Armstrong PW; Starling RC; O'Connor CM; Hernandez AF; Califf RM
J Card Fail; 2013 Sep; 19(9):611-20. PubMed ID: 24054337
[TBL] [Abstract][Full Text] [Related]
16. A rational approach for the treatment of acute heart failure: current strategies and future options.
Sharma M; Teerlink JR
Curr Opin Cardiol; 2004 May; 19(3):254-63. PubMed ID: 15096959
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of patients hospitalized for acute decompensated heart failure: does nesiritide make a difference?
Carroll RJ; Mulla ZD; Hauck LD; Westbrook A
BMC Cardiovasc Disord; 2007 Nov; 7():37. PubMed ID: 18039381
[TBL] [Abstract][Full Text] [Related]
18. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study.
Burger AJ; Horton DP; LeJemtel T; Ghali JK; Torre G; Dennish G; Koren M; Dinerman J; Silver M; Cheng ML; Elkayam U;
Am Heart J; 2002 Dec; 144(6):1102-8. PubMed ID: 12486437
[TBL] [Abstract][Full Text] [Related]
19. Home inotropic therapy in advanced heart failure: cost analysis and clinical outcomes.
Harjai KJ; Mehra MR; Ventura HO; Lapeyre YM; Murgo JP; Stapleton DD; Smart FW
Chest; 1997 Nov; 112(5):1298-303. PubMed ID: 9367472
[TBL] [Abstract][Full Text] [Related]
20. Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure.
Aronson D; Burger AJ
Am Heart J; 2004 Nov; 148(5):e16. PubMed ID: 15523294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
